APC: Scott on Scripps

Last chance to vote

Have you voted in APC Board elections? Your voice matters! Voting is open until this coming Monday, October 21, 2024 at 11:59 pm EDT, so be sure to cast your ballot by then. read more →
Scott on Scripps

APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide. read more →
BREAKING: FDA allows renewed compounding of tirzepatide copies — for now

In a win for continued patient access to compounded versions of Eli Lilly’s Mounjaro and Zepbound, FDA clarified today that pharmacies may continue to prepare copies of those FDA-approved drugs, at least for now. read more →
FDA issues IV fluids emergency guidance

The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage. read more →
Welcome aboard, GYMA

It's our newest tier-level corporate patron. read more →
The Journey to Earning the CPhT-Adv Certification from PTCB

Earning the Advanced Certified Pharmacy Technician Certification from the Pharmacy Technician Certification Board is a great way to boost your professional skills and career opportunities. read more →
Technicians: Professional Development through Mentorship

Mentors play a crucial role in career advancement by offering guidance, encouragement, advocacy, and networking potential. Identifying the right mentor within your industry is essential. read more →
FDA reconsiders on tirzepatide, big questions remain

After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list. read more →

October 18, 2024

Scott on Scripps

APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.

But wait, there’s more — lots more

We can’t keep up with all the places APC has been interviewed or at least quoted just in the past week. Here’s a sampling:

Fox Business: Eli Lilly’s tirzepatide is off the FDA’s shortage list: What it means for patients
USA Today: There’s a big Ozempic controversy brewing online. Doctors say it’s the ‘wild west.’
Everyday Health: Are Compounded Weight Loss Drugs on Their Way Out?
Inside Health Policy: FDA Tells Court It Will Reconsider Removing Tirzepatide From Shortage List
Inside Health Policy: APC Advises Compounders To Halt Tirzepatide Production Until FDA Clarifies Stance
Barron’s: FDA Reversal on Knockoff GLP-1 Drugs Brings Confusion, and Few Answers
Scripps News: Scott’s Live Interview with Scripps
NBC News: Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
News Reports: FDA reconsiders removal of tirzepatide shortage
FiercePharma: In win for compounders, FDA will review its decision to put Eli Lilly’s tirzepatide on shortage list
The Hill: FDA shakes up weight loss market as Mounjaro shortage ends
The Pinnacle Gazette: Legal Battles Erupt Over Knockoff Weight Loss Drugs
Parcel Health: The Zepbound Shortage: Resolved for Whom?
Speciality Pharmacy Continuum: ‘Tail Period’ for Compounders Could Ease Weight-Loss Rx Shortages
Quartz: Knockoff weight loss drug sellers are fighting back against Eli Lilly and the FDA
Wired: The Crackdown on Compounded GLP-1 Meds Has Begun
Bloomberg: Novo Study Finds Copycat Weight-Loss Drugs Are Low Quality
Bloomberg: Lilly Fires Warning Shot at Copycat Drug Makers After Shortage
650 Keni (Alaska): Popular Weight Loss Drugs To Become More Expensive As Shortage Ends
CNN: The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Wired: A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Axios: WeightWatchers to offer compounded GLP-1 weight-loss drugs
Medscape: Tirzepatide Shortage Resolved? FDA Says Yes, Compounders No

Big Buttons

More News

» More APC News «

Scott on Scripps

But wait, there’s more — lots more